Jci_page_head_homepage_01 Jci_page_head_homepage_02
Louis J. Picker, Edward F. Reed-Inderbitzin, Shoko I. Hagen, John B. Edgar, Scott G. Hansen, Alfred Legasse, Shannon Planer, Michael Piatak, Jeffrey D. Lifson, Vernon C. Maino, Michael K. Axthelm, Francois Villinger
Published in Volume 116, Issue 6
J Clin Invest. 2006; 116(6):1514–1524 doi:10.1172/JCI27564
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4
IL-15 responsiveness is limited by the availability of response-capable cells, but not by development of an anti–IL-15 antibody response.

(A) The expression of Ki-67 within the CD28 subset of circulating CD4+ and CD8+ memory T cells is shown over time in a healthy, adult (IL-15–naive) RM receiving 2 courses of IL-15 therapy 70 days apart. Each black box represents 2 doses of IL-15 (each dose 10 μg/kg). Note that the second response was of a magnitude similar to or greater than that of the initial response. (B) The figure shows successive histograms of Ki-67 expression on gated CD28CCR7, CD4+ memory T cells from an RM (no. 18743) that received 10 μg/kg IL-15 on days 0, 3, 7, and 10 (see Figure 2 for overall quantitative data). The arrows (black, blue, red, and green) delineate successive waves of Ki-67 expression (see text). *IL-15 dose given on indicated days.